Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation

Razaghi, Ali, Owens, Leigh, and Heimann, Kirsten (2016) Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation. Journal of Biotechnology, 240. pp. 48-60.

[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website: http://dx.doi.org/10.1016/j.jbiotec.2016...
 
2
2


Abstract

Human interferon gamma is a cytokine belonging to a diverse group of interferons which have a crucial immunological function against mycobacteria and a wide variety of viral infections. To date, it has been approved for treatment of chronic granulomatous disease and malignant osteopetrosis, and its application as an immunotherapeutic agent against cancer is an increasing prospect. Recombinant human interferon gamma, as a lucrative biopharmaceutical, has been engineered in different expression systems including prokaryotic, protozoan, fungal (yeasts), plant, insect and mammalian cells. Human interferon gamma is commonly expressed in Escherichia coli, marketed as ACTIMMUNE®, however, the resulting product of the prokaryotic expression system is unglycosylated with a short half-life in the bloodstream; the purification process is tedious and makes the product costlier. Other expression systems also did not show satisfactory results in terms of yields, the biological activity of the protein or economic viability. Thus, the review aims to synthesise available information from previous studies on the production of human interferon gamma and its glycosylation patterns in different expression systems, to provide direction to future research in this field.

Item ID: 48140
Item Type: Article (Refereed Research - C1)
Keywords: protein expression & purification; glycosylation; actimmune; biopharmaceutical; cancer immunotherapy; interferon gamma
Additional Information:

Chemical compounds studied in this article:

Asparagine: (PubChem CID: 6267)

Fucose: (PubChem CID: 17106)

Galactose: (PubChem CID: 6036)

Guanidinium hydrochloride: (PubChem CID:5742)

Mannose: (PubChem CID: 18950)

Methionine: (PubChem CID: 6137)

N-acetyl glucosamine: (PubChem CID: 24139)

N-acetylneuraminic acid (PubChem CID: 439197)

Oxaliplatin: (PubChem CID: 429863)

Pyroglutamate: (PubChem CID: 23668602)

Sepharose: (PubChem CID: 11966311)

Urea: (PubChem CID: 1176)

ISSN: 1873-4863
Funders: Advanced Manufacturing Cooperative Research Centre (AMCRC)
Projects and Grants: AMCRC grant number 2.3.4
Date Deposited: 31 Mar 2017 01:47
FoR Codes: 10 TECHNOLOGY > 1004 Medical Biotechnology > 100499 Medical Biotechnology not elsewhere classified @ 20%
10 TECHNOLOGY > 1003 Industrial Biotechnology > 100399 Industrial Biotechnology not elsewhere classified @ 80%
SEO Codes: 86 MANUFACTURING > 8608 Human Pharmaceutical Products > 860803 Human Pharmaceutical Treatments (e.g. Antibiotics) @ 100%
Downloads: Total: 2
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page